StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

Research analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

Shares of OPGN stock opened at $5.18 on Friday. OpGen has a 52-week low of $0.53 and a 52-week high of $5.30. The company’s 50 day moving average is $3.21 and its 200 day moving average is $1.95.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.